Are you over 18 and want to see adult content?
More Annotations
A complete backup of seminitresepi.com
Are you over 18 and want to see adult content?
A complete backup of loxy.bigcartel.com
Are you over 18 and want to see adult content?
A complete backup of peoplemagazine.co.za
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of consumerenergyalliance.org
Are you over 18 and want to see adult content?
A complete backup of jonesaroundtheworld.com
Are you over 18 and want to see adult content?
A complete backup of u-bretagneloire.fr
Are you over 18 and want to see adult content?
A complete backup of freiwilligendienste-kultur-bildung.de
Are you over 18 and want to see adult content?
Text
biosimilars
MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. PORTFOLIO: IN CONSTANT PROGRESSION At mAbxience we are working to increase patient access to high quality medicines. Highly attractive portfolio targeting the areas of hematology, oncology, osteoporosis and pediatrics. With two approved products (MB01 rituximab and MB02 bevacizumab, since 2014 and 2016 respectively) and new products in development: mAbxience developsbiosimilars
MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad.NEWS - MABXIENCE
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB. 03/25/2021. Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most TEAM | MABXIENCE | FROM LAB TO LIFE Emmanuelle Lepine is mAbxience General Manager. She brings to mAbxience over 20 years of experience in the pharmaceutical and biotechnology industry. Emmanuelle is a recognized leader, with hands on experience in establishing and leading successful companies. With her global expertise, Emmanuelle has been supporting organizations to LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo OUR SUCCESSFUL STORY Our. successful story. • European Commission approval for our MB02 bevacizumab. Launched across a multiple markets in Europe. • Manufacture of the AstraZeneca/Oxford Covid19 Vaccine. • New state-of-the-art mAbxience biomanufacturing facility opening inArgentina. •
AN INTERNATIONAL COMPANY AN INTERNATIONAL. COMPANY. Our 3 multiproduct facilities committed to global quality standards implement the latest state of the art technology to support our products worldwide. Our headquarters are based in Madrid (Spain), with a facility in León (Spain), and two facilities in Buenos Aires (Argentina)”. Phone: +54 11 4762 77 00. SPAIN’S MABXIENCE BOOSTING BIOLOGICS CAPACITY WITH 4,000 L SUB Spain’s mAbxience boosting biologics. capacity with 4,000 L SUB. 03/25/2021. Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first inEurope
LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin FILL & FINISH PARTNERS Fill &Finish Partners. Fill &. Finish Partners. For the filling of its finished products, mAbxience is in partnership with the facilities of Sinergium Biotech in Argentina and Universal Farma in Spain. Universal Farma is part of the Insud Pharma Group and complies with GMP regulations and the strictest FDA and EMA quality standards. MONOCLONAL ANTIBODY PRODUCTION 1. Attainment in the laboratory. The industrial production of monoclonal antibodies starts in the laboratory 3 by inserting an antigen (a molecule that can trigger immune response) into a mouse. The mouse starts to produce B lymphocytes (antibody-producing cells) to defend itself against the antigen 4. These cells have a short lifespan and
MCB (MASTER CELL BANK) MCB (MASTER CELL BANK) An aliquot of a single pool of cells that generally has been prepared from the selected cell clone under defined conditions, dispensed into multiple containers, and stored under defined conditions. The MCB is used to derive all working cell banks. The testing performed on a new MCB (from a previous initial cellclone, MCB
MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. PORTFOLIO: IN CONSTANT PROGRESSION At mAbxience we are working to increase patient access to high quality medicines. Highly attractive portfolio targeting the areas of hematology, oncology, osteoporosis and pediatrics. With two approved products (MB01 rituximab and MB02 bevacizumab, since 2014 and 2016 respectively) and new products in development: mAbxience developsbiosimilars
MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. PORTFOLIO: IN CONSTANT PROGRESSION At mAbxience we are working to increase patient access to high quality medicines. Highly attractive portfolio targeting the areas of hematology, oncology, osteoporosis and pediatrics. With two approved products (MB01 rituximab and MB02 bevacizumab, since 2014 and 2016 respectively) and new products in development: mAbxience developsbiosimilars
MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad.NEWS - MABXIENCE
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB. 03/25/2021. Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most TEAM | MABXIENCE | FROM LAB TO LIFE Emmanuelle Lepine is mAbxience General Manager. She brings to mAbxience over 20 years of experience in the pharmaceutical and biotechnology industry. Emmanuelle is a recognized leader, with hands on experience in establishing and leading successful companies. With her global expertise, Emmanuelle has been supporting organizations to LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo OUR SUCCESSFUL STORY Our. successful story. • European Commission approval for our MB02 bevacizumab. Launched across a multiple markets in Europe. • Manufacture of the AstraZeneca/Oxford Covid19 Vaccine. • New state-of-the-art mAbxience biomanufacturing facility opening inArgentina. •
AN INTERNATIONAL COMPANY AN INTERNATIONAL. COMPANY. Our 3 multiproduct facilities committed to global quality standards implement the latest state of the art technology to support our products worldwide. Our headquarters are based in Madrid (Spain), with a facility in León (Spain), and two facilities in Buenos Aires (Argentina)”. Phone: +54 11 4762 77 00. SPAIN’S MABXIENCE BOOSTING BIOLOGICS CAPACITY WITH 4,000 L SUB Spain’s mAbxience boosting biologics. capacity with 4,000 L SUB. 03/25/2021. Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first inEurope
LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin FILL & FINISH PARTNERS Fill &Finish Partners. Fill &. Finish Partners. For the filling of its finished products, mAbxience is in partnership with the facilities of Sinergium Biotech in Argentina and Universal Farma in Spain. Universal Farma is part of the Insud Pharma Group and complies with GMP regulations and the strictest FDA and EMA quality standards. MONOCLONAL ANTIBODY PRODUCTION 1. Attainment in the laboratory. The industrial production of monoclonal antibodies starts in the laboratory 3 by inserting an antigen (a molecule that can trigger immune response) into a mouse. The mouse starts to produce B lymphocytes (antibody-producing cells) to defend itself against the antigen 4. These cells have a short lifespan and
MCB (MASTER CELL BANK) MCB (MASTER CELL BANK) An aliquot of a single pool of cells that generally has been prepared from the selected cell clone under defined conditions, dispensed into multiple containers, and stored under defined conditions. The MCB is used to derive all working cell banks. The testing performed on a new MCB (from a previous initial cellclone, MCB
MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
PORTFOLIO: IN CONSTANT PROGRESSION At mAbxience we are working to increase patient access to high quality medicines. Highly attractive portfolio targeting the areas of hematology, oncology, osteoporosis and pediatrics. With two approved products (MB01 rituximab and MB02 bevacizumab, since 2014 and 2016 respectively) and new products in development: mAbxience developsbiosimilars
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. BIOEQUIVALENCIA ¿QUÉ ES LA BIOEQUIVALENCIA Y PARA …TRANSLATE THISPAGE
BIOEQUIVALENCIA. La bioequivalencia es una propiedad existente entre dos o varios medicamentos que presentan un comportamiento equivalente en el organismo. En el caso de los biosimilares, tras demostrar biosimilaridad físico-química y funcional a nivel de pruebas in vitro, se establece bioequivalencia clínica a nivel farmacocinéticoy
PROCESO DE PRODUCCIÓN DE ANTICUERPOS …TRANSLATE THIS PAGESEE MOREON MABXIENCE.COM
MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
PORTFOLIO: IN CONSTANT PROGRESSION At mAbxience we are working to increase patient access to high quality medicines. Highly attractive portfolio targeting the areas of hematology, oncology, osteoporosis and pediatrics. With two approved products (MB01 rituximab and MB02 bevacizumab, since 2014 and 2016 respectively) and new products in development: mAbxience developsbiosimilars
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. BIOEQUIVALENCIA ¿QUÉ ES LA BIOEQUIVALENCIA Y PARA …TRANSLATE THISPAGE
BIOEQUIVALENCIA. La bioequivalencia es una propiedad existente entre dos o varios medicamentos que presentan un comportamiento equivalente en el organismo. En el caso de los biosimilares, tras demostrar biosimilaridad físico-química y funcional a nivel de pruebas in vitro, se establece bioequivalencia clínica a nivel farmacocinéticoy
PROCESO DE PRODUCCIÓN DE ANTICUERPOS …TRANSLATE THIS PAGESEE MOREON MABXIENCE.COM
NEWS - MABXIENCE
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB. 03/25/2021. Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. TECNOLOGÍA SINGLE-USE Nuestras instalaciones están equipadas con la tecnología más innovadora del sector. Tecnología de biorreactores single-use. Utilizamos tecnología de biorreactores de un solo uso (single-use technology) a gran escala que permite ahorrar en los recursos empleados durante el proceso de producción. QUÉ ES UN HAPTENO? HAPTENO. El hapteno es una sustancia de bajo peso molecular que, sola, puede reaccionar con su anticuerpo correspondiente. Para ser inmunógenos, los haptenos se unen a moléculas con pesos moleculares superiores a 5000. Un ejemplo sería el hapteno digoxina unido mediante enlace covalente a albúmina sérica bovina, formando elinmunógeno de
DIFERENCIAS ENTRE MEDICAMENTOS GENÉRICOS, …TRANSLATE THIS PAGE Medicamentos Genéricos. A diferencia de los medicamentos genéricos, desarrollados en un proceso de síntesis química, los medicamentos biológicos son aquellos medicamentos que contienen uno o más principios activos producidos o derivados de una fuente biológica, entre los que se incluyen un amplio abanico de productos como las vacunas, hemoderivados, alérgenos, terapias celulares EXTRAPOLACIÓN ¿QUÉ ES LA EXTRAPOLACIÓN Y PARA QUÉ …TRANSLATETHIS PAGE
EXTRAPOLACIÓN. La extrapolación hace referencia a la aprobación de un medicamento biosimilar para el tratamiento de enfermedades o condiciones para las que no ha sido estudiado de manera específica. Esta aprobación se basa en el elevado grado de similaridad existenteentre el
MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. BIOEQUIVALENCIA ¿QUÉ ES LA BIOEQUIVALENCIA Y PARA …TRANSLATE THISPAGE
BIOEQUIVALENCIA. La bioequivalencia es una propiedad existente entre dos o varios medicamentos que presentan un comportamiento equivalente en el organismo. En el caso de los biosimilares, tras demostrar biosimilaridad físico-química y funcional a nivel de pruebas in vitro, se establece bioequivalencia clínica a nivel farmacocinéticoy
PROCESO DE PRODUCCIÓN DE ANTICUERPOS …TRANSLATE THIS PAGESEE MOREON MABXIENCE.COM
MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. BIOEQUIVALENCIA ¿QUÉ ES LA BIOEQUIVALENCIA Y PARA …TRANSLATE THISPAGE
BIOEQUIVALENCIA. La bioequivalencia es una propiedad existente entre dos o varios medicamentos que presentan un comportamiento equivalente en el organismo. En el caso de los biosimilares, tras demostrar biosimilaridad físico-química y funcional a nivel de pruebas in vitro, se establece bioequivalencia clínica a nivel farmacocinéticoy
PROCESO DE PRODUCCIÓN DE ANTICUERPOS …TRANSLATE THIS PAGESEE MOREON MABXIENCE.COM
MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research GENERICS, BIOLOGICS, BIOSIMILARS: WHO’S WHO? biosimilars: who’s who? Unlike generic medicines, manufactured through chemical synthesis, biologic medicines contain one or more active principles produced or derived from a biologic source, include a wide range of products like vaccines, allergens or recombinant proteins. 4. Most biologics, such as monoclonal antibodies, have ahighly
INSUD PHARMA SECURES "EXCELLENT" RATING IN THE PROFARMA It is a recognition of the brands of the group Chemo, Exeltis and mAbxience for their commitment to industrial development and investment in our country LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
PRESENTACIÓN DE POWERPOINT In mAbxience we work to ensure that each product is similar to the original, with the same genetic fidelity, and with the precision of a human footprint. We do this to secure quality and efficiency; it isnot a
EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. CONTACTO DE MABXIENCE, LA COMPAÑÍA …TRANSLATE THIS PAGE Si quieres ponerte en contacto con mAbxience, la compañía biotecnológica española, puedes hacerlo entrando en nuestra web.Te esperamos!
TECNOLOGÍA SINGLE-USE Nuestras instalaciones están equipadas con la tecnología más innovadora del sector. Tecnología de biorreactores single-use. Utilizamos tecnología de biorreactores de un solo uso (single-use technology) a gran escala que permite ahorrar en los recursos empleados durante el proceso de producción. DETERMINANTE ANTIGÉNICO DETERMINANTE ANTIGÉNICO. La parte específica de una estructura de un antígeno que inducirá una respuesta inmunitaria, es decir, se unirá a los receptores de los linfocitos T y B y también podrá experimentar reacciones con los anticuerpos producidos. MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. BIOEQUIVALENCIA ¿QUÉ ES LA BIOEQUIVALENCIA Y PARA …TRANSLATE THISPAGE
BIOEQUIVALENCIA. La bioequivalencia es una propiedad existente entre dos o varios medicamentos que presentan un comportamiento equivalente en el organismo. En el caso de los biosimilares, tras demostrar biosimilaridad físico-química y funcional a nivel de pruebas in vitro, se establece bioequivalencia clínica a nivel farmacocinéticoy
PROCESO DE PRODUCCIÓN DE ANTICUERPOS …TRANSLATE THIS PAGESEE MOREON MABXIENCE.COM
MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. BIOEQUIVALENCIA ¿QUÉ ES LA BIOEQUIVALENCIA Y PARA …TRANSLATE THISPAGE
BIOEQUIVALENCIA. La bioequivalencia es una propiedad existente entre dos o varios medicamentos que presentan un comportamiento equivalente en el organismo. En el caso de los biosimilares, tras demostrar biosimilaridad físico-química y funcional a nivel de pruebas in vitro, se establece bioequivalencia clínica a nivel farmacocinéticoy
PROCESO DE PRODUCCIÓN DE ANTICUERPOS …TRANSLATE THIS PAGESEE MOREON MABXIENCE.COM
MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research GENERICS, BIOLOGICS, BIOSIMILARS: WHO’S WHO? biosimilars: who’s who? Unlike generic medicines, manufactured through chemical synthesis, biologic medicines contain one or more active principles produced or derived from a biologic source, include a wide range of products like vaccines, allergens or recombinant proteins. 4. Most biologics, such as monoclonal antibodies, have ahighly
INSUD PHARMA SECURES "EXCELLENT" RATING IN THE PROFARMA It is a recognition of the brands of the group Chemo, Exeltis and mAbxience for their commitment to industrial development and investment in our country LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
PRESENTACIÓN DE POWERPOINT In mAbxience we work to ensure that each product is similar to the original, with the same genetic fidelity, and with the precision of a human footprint. We do this to secure quality and efficiency; it isnot a
EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. CONTACTO DE MABXIENCE, LA COMPAÑÍA …TRANSLATE THIS PAGE Si quieres ponerte en contacto con mAbxience, la compañía biotecnológica española, puedes hacerlo entrando en nuestra web.Te esperamos!
TECNOLOGÍA SINGLE-USE Nuestras instalaciones están equipadas con la tecnología más innovadora del sector. Tecnología de biorreactores single-use. Utilizamos tecnología de biorreactores de un solo uso (single-use technology) a gran escala que permite ahorrar en los recursos empleados durante el proceso de producción. DETERMINANTE ANTIGÉNICO DETERMINANTE ANTIGÉNICO. La parte específica de una estructura de un antígeno que inducirá una respuesta inmunitaria, es decir, se unirá a los receptores de los linfocitos T y B y también podrá experimentar reacciones con los anticuerpos producidos. MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. BIOEQUIVALENCIA ¿QUÉ ES LA BIOEQUIVALENCIA Y PARA …TRANSLATE THISPAGE
BIOEQUIVALENCIA. La bioequivalencia es una propiedad existente entre dos o varios medicamentos que presentan un comportamiento equivalente en el organismo. En el caso de los biosimilares, tras demostrar biosimilaridad físico-química y funcional a nivel de pruebas in vitro, se establece bioequivalencia clínica a nivel farmacocinéticoy
PROCESO DE PRODUCCIÓN DE ANTICUERPOS …TRANSLATE THIS PAGESEE MOREON MABXIENCE.COM
MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the EUROPEAN COMMISSION APPROVES MABXIENCE'S BEVACIZUMAB FOR The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe. MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatmentof carcinoma of
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM COMPAÑÍA BIOTECNOLÓGICA ESPECIALIZADA EN …TRANSLATE THIS PAGE Compañía biotecnológica especializada en biosimilares. Nuestra misión es ofrecer soluciones y esperanza al mayor número de personas. Esto es posible gracias a los medicamentos biosimilares, que facilitan la accesibilidad a diversos tratamientos y contribuyen a la sostenibilidad de los sistemas de salud a nivel mundial. Más info. EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. BIOEQUIVALENCIA ¿QUÉ ES LA BIOEQUIVALENCIA Y PARA …TRANSLATE THISPAGE
BIOEQUIVALENCIA. La bioequivalencia es una propiedad existente entre dos o varios medicamentos que presentan un comportamiento equivalente en el organismo. En el caso de los biosimilares, tras demostrar biosimilaridad físico-química y funcional a nivel de pruebas in vitro, se establece bioequivalencia clínica a nivel farmacocinéticoy
PROCESO DE PRODUCCIÓN DE ANTICUERPOS …TRANSLATE THIS PAGESEE MOREON MABXIENCE.COM
MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research GENERICS, BIOLOGICS, BIOSIMILARS: WHO’S WHO? biosimilars: who’s who? Unlike generic medicines, manufactured through chemical synthesis, biologic medicines contain one or more active principles produced or derived from a biologic source, include a wide range of products like vaccines, allergens or recombinant proteins. 4. Most biologics, such as monoclonal antibodies, have ahighly
INSUD PHARMA SECURES "EXCELLENT" RATING IN THE PROFARMA It is a recognition of the brands of the group Chemo, Exeltis and mAbxience for their commitment to industrial development and investment in our country LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
PRESENTACIÓN DE POWERPOINT In mAbxience we work to ensure that each product is similar to the original, with the same genetic fidelity, and with the precision of a human footprint. We do this to secure quality and efficiency; it isnot a
EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. CONTACTO DE MABXIENCE, LA COMPAÑÍA …TRANSLATE THIS PAGE Si quieres ponerte en contacto con mAbxience, la compañía biotecnológica española, puedes hacerlo entrando en nuestra web.Te esperamos!
TECNOLOGÍA SINGLE-USE Nuestras instalaciones están equipadas con la tecnología más innovadora del sector. Tecnología de biorreactores single-use. Utilizamos tecnología de biorreactores de un solo uso (single-use technology) a gran escala que permite ahorrar en los recursos empleados durante el proceso de producción. DETERMINANTE ANTIGÉNICO DETERMINANTE ANTIGÉNICO. La parte específica de una estructura de un antígeno que inducirá una respuesta inmunitaria, es decir, se unirá a los receptores de los linfocitos T y B y también podrá experimentar reacciones con los anticuerpos producidos. MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
OUR SUCCESSFUL STORY Our. successful story. • European Commission approval for our MB02 bevacizumab. Launched across a multiple markets in Europe. • Manufacture of the AstraZeneca/Oxford Covid19 Vaccine. • New state-of-the-art mAbxience biomanufacturing facility opening inArgentina. •
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad. MABXIENCE | BIOPHARMACEUTICAL COMPANY SPECIALIZED INCONTACT USCSRESPAÑOLCOMPANYMANUFACTURINGCDMO mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world. mAbNEWS. MABXIENCE ENTERS INTO AN AGREEMENT WITH ASTRAZENECA TO mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico tocomplete the
OUR SUCCESSFUL STORY Our. successful story. • European Commission approval for our MB02 bevacizumab. Launched across a multiple markets in Europe. • Manufacture of the AstraZeneca/Oxford Covid19 Vaccine. • New state-of-the-art mAbxience biomanufacturing facility opening inArgentina. •
LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo BIOSIMILAR'S MANUFACTURING PROCESS This opens in a new window. As the video shows, biosimilars are manufactured by means of a complex process that can be broken down into seven phases: 1. Preparation of the material. 2. Preparation of fluids. 3. Cellular expansion, which is essentially the MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR mAbxience and Amneal enter. into an agreement for bevacizumab biosimilar in the United States. 05/23/2018. The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment. Madrid, May 23, 2018– mAbxience, a company specialized in the research LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin CLINICAL STUDY TRIAL CLINICAL STUDY TRIAL. Study with the objective of determining how a medicine is handled by, and affects, humans. Clinical studies or trials are conducted in healthy volunteers or in patients. Pivotal clinical studies involving a larger group of patients provide evidence on whether the medicine can be considered both safe and effective in areal
ARGENTINA – MABXIENCE BUENOS AIRES – GARÍNTRANSLATE THIS PAGESEE MORE ON MABXIENCE.COM EMPLEO EN MABXIENCE, CONSULTA NUESTRAS OFERTAS DE …TRANSLATE THISPAGE
Desde mAbxience creemos que un equipo humano, comprometido y altamente involucrado con el sector en el que desarrolla su actividad profesional es el activo más valioso para una empresa que, como nosotros, apuesta por la innovación, el dinamismo y la flexibilidad.NEWS - MABXIENCE
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB. 03/25/2021. Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in mostCOMPANY OVERVIEW
Dr. Hugo Sigman. Dr. Sigman and his biochemist wife, Dr. Silvia Gold, founded mAbxience in 2010 as the biotechnology arm of Insud Pharma, which the couple set up in 1977. Hugo Sigman is a trained physician (University of Buenos Aires), specialising in psychiatry. He launched the Research, Development and Innovation Consortium (ID+i) to focus on TEAM | MABXIENCE | FROM LAB TO LIFE Emmanuelle Lepine is mAbxience General Manager. She brings to mAbxience over 20 years of experience in the pharmaceutical and biotechnology industry. Emmanuelle is a recognized leader, with hands on experience in establishing and leading successful companies. With her global expertise, Emmanuelle has been supporting organizations to LOCATIONS | MABXIENCE | FROM LAB TO LIFE Via Maggio, 1, 6900-Lugano, Switzerland, Ph: +41 91 973 14 23 || mAbxience URUGUAY. Yaguarón, 1407 Office 904. Torre de los Profesionales. 11100 – Montevideo OUR SUCCESSFUL STORY Our. successful story. • European Commission approval for our MB02 bevacizumab. Launched across a multiple markets in Europe. • Manufacture of the AstraZeneca/Oxford Covid19 Vaccine. • New state-of-the-art mAbxience biomanufacturing facility opening inArgentina. •
PORTFOLIO: IN CONSTANT PROGRESSION At mAbxience we are working to increase patient access to high quality medicines. Highly attractive portfolio targeting the areas of hematology, oncology, osteoporosis and pediatrics. With two approved products (MB01 rituximab and MB02 bevacizumab, since 2014 and 2016 respectively) and new products in development: mAbxience developsbiosimilars
AN INTERNATIONAL COMPANY AN INTERNATIONAL. COMPANY. Our 3 multiproduct facilities committed to global quality standards implement the latest state of the art technology to support our products worldwide. Our headquarters are based in Madrid (Spain), with a facility in León (Spain), and two facilities in Buenos Aires (Argentina)”. Phone: +54 11 4762 77 00. LYMPHOMA AND BIOLOGIC TREATMENTS Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may also be affected. The disease consists of an alteration of the immune system . The more the disease has spread, the more severe the alteration is. There are two main types of lymphoma: Hodgkin lymphoma, or Hodgkin MONOCLONAL ANTIBODY PRODUCTION 1. Attainment in the laboratory. The industrial production of monoclonal antibodies starts in the laboratory 3 by inserting an antigen (a molecule that can trigger immune response) into a mouse. The mouse starts to produce B lymphocytes (antibody-producing cells) to defend itself against the antigen 4. These cells have a short lifespan and
MCB (MASTER CELL BANK) MCB (MASTER CELL BANK) An aliquot of a single pool of cells that generally has been prepared from the selected cell clone under defined conditions, dispensed into multiple containers, and stored under defined conditions. The MCB is used to derive all working cell banks. The testing performed on a new MCB (from a previous initial cellclone, MCB
__
Our mission is to deliver solutions and bring hope to as many peopleas possible.
Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcaresystems worldwide.
More info
__
Growth driven by passion and commitment, enabling us to enter any market and adapt to challenges with dedication and talent.More info
__
Trust built on the values and the experience of a dynamic, multi-disciplinary and highly qualified team. The application of a unified work methodology, with a focus on quality in everything we do.More info
__
Our mission is to deliver solutions and bring hope to as many peopleas possible.
Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcaresystems worldwide.
More info
__
Growth driven by passion and commitment, enabling us to enter any market and adapt to challenges with dedication and talent.More info
__
Trust built on the values and the experience of a dynamic, multi-disciplinary and highly qualified team. The application of a unified work methodology, with a focus on quality in everything we do.More info
Skip to content
* Contact us
* General Contact
* Business Development Contact* CSR
* Insud Pharma
* Español
Toggle navigation
* Company
* About us
* CEO Message
* Leadership Team
* Business Growth story* Manifesto
* Our locations
* R&D
* Biosimilars
* Portfolio
* Quality by design
* Manufacturing
* Single-Use Technology* Facilities
* CDMO
* Partnerships
* B2B (Business to Business)* Media
* News
* What’s next? Meet us at…* Blog mAbxience
* Jobs
* Company
* About us
* CEO Message
* Leadership Team
* Business Growth story* Manifesto
* Our locations
* R&D
* Biosimilars
* Portfolio
* Quality by design
* Manufacturing
* Single-Use Technology* Facilities
* CDMO
* Partnerships
* B2B (Business to Business)* Media
* News
* What’s next? Meet us at…* Blog mAbxience
* Jobs
* Contact us
* General Contact
* Business Development Contact* CSR
* Insud Pharma
* Español
CREATING STRONG
VALUE IN BIOSIMILARSWHO WE ARE
MABXIENCE IS A SPANISH FULLY-FLEDGED BIOTECH COMPANY WITH A DECADE OF EXPERIENCE IN DEVELOPING AND MANUFACTURING BIOSIMILARS. Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world.MABNEWS
MABXIENCE INAUGURATES NEW MONOCLONAL ANTIBODY BIOSIMILAR PLANT INARGENTINA
24/02/2020 +
DOCTOR SILVIA GOLD AWARDED GOLD MEDAL BY THE ROYAL ACADEMY OF MEDICINE AND SURGERY OF MURCIA20/05/2019 +
WHAT’S NEXT? MEET US AT... CPHI & BIO-EUROPE 2020 Meet us at BIO-Europe, to be held 23 – 25 March in Paris, France Meet us at CPHI, to be held 13-15 October in Milan, Italia+
PARTNERSHIPS
Our business model is B2B (business to business), with global partnership network of key market leaders in the EU, US, Japan andemerging markets.
+
*
*
*
* Portfolio
* Blog mAbxience
* Contact Us
* Privacy & Terms
* Cookies Policy
* Glossary
2019 mAbxience. Compañía biotecnológica especializada enbiosimilares
We use own cookies and third-party cookies to improve the accessibility to the website, our services and offer you personalised advertising based on your preferences and browsing habits. If you interact with different website elements or continue scrolling down this website for 10 seconds or more, you accept the use and installation of these cookies. For further information, please visit our Cookies Policy . To personalise or disable the use of cookies click here.
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0